-
Start Preamble
Start Printed Page 79064
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule.
SUMMARY:
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for a new animal drug application (NADA) for zinc gluconate injectable solution from Technology Transfer, Inc., to Ark Sciences, Inc.
DATES:
This rule is effective December 21, 2011.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, (240) 276-8300, email: steven.vaughn@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
Technology Transfer, Inc., 33 East Broadway, suite 190, Columbia, MO 65203 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-217 for NEUTERSOL (zinc gluconate) Injectable Solution to Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218. Accordingly, the Agency is amending the regulations in 21 CFR 522.2690 to reflect the transfer of ownership.
Following this change of sponsorship, Technology Transfer, Inc., is no longer the sponsor of an approved application. Accordingly, § 510.600 (21 CFR 510.600) is being amended to remove the entries for this firm.
In addition, Ark Sciences, Inc., is not currently listed in the animal drug regulations as a sponsor of an approved application. Accordingly, § 510.600 is being amended to add entries for this sponsor.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
Start List of SubjectsList of Subjects
21 CFR Part 510
- Administrative practice and procedure
- Animal drugs
- Labeling
- Reporting and recordkeeping requirements
21 CFR Part 522
- Animal drugs
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510 and 522 are amended as follows:
Start PartPART 510—NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for 21 CFR part 510 continues to read as follows:
End Amendment Part Start Amendment Part2. In § 510.600, in the table in paragraph (c)(1), remove the entry for “Technology Transfer, Inc.”; alphabetically add a new entry for “Ark Sciences, Inc.”; and in the table in paragraph (c)(2), remove the entry for “067647”; and in numerical sequence add a new entry for “076175” to read as follows:
End Amendment PartNames, addresses, and drug labeler codes of sponsors of approved applications.* * * * *(c) * * *
(1) * * *
Firm name and address Drug labeler code * * * * * Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218 076175 * * * * * (2) * * *
Drug labeler code Firm name and address * * * * * 076175 Ark Sciences, Inc., 1101 East 33rd St., suite B304, Baltimore, MD 21218. * * * * * PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part3. The authority citation for 21 CFR part 522 continues to read as follows:
End Amendment Part[Amended]4. In paragraph (b) of § 522.2690, remove “067647” and in its place add “076175”.
End Amendment Part Start SignatureDated: December 8, 2011.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. 2011-32591 Filed 12-20-11; 8:45 am]
BILLING CODE 4160-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 12/21/2011
- Published:
- 12/21/2011
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule.
- Document Number:
- 2011-32591
- Dates:
- This rule is effective December 21, 2011.
- Pages:
- 79064-79064 (1 pages)
- Docket Numbers:
- Docket No. FDA-2011-N-0003
- Topics:
- Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements
- PDF File:
- 2011-32591.pdf
- Supporting Documents:
- » Freedom of Information Summary NADA 141-324 Phenylpropanolamine
- » Freedom of Information Summary NADA 141-331 Pergolide
- » Freedom of Information Summary NADA 141-333 - Milbemycin Oxime, Lufenuron, and Praziquantel
- » Freedom of Information Summary NADA 095-735 - Monensin
- » Freedom of Information Summary NADA 141-207 - Danofloxacin
- » Freedom of Information Summary NADA 141-322 - Gonadotropin Releasing Factor Analog-Diphtheria Toxoid Conjugate
- » Freedom of Information Summary ANDA 200-494 - Gentamicin Sulfate
- » reedom of Information Summary NADA 141-203 Deracoxib
- » Gentamicin Topical Spray (gentamicin sulfate, betamethasone valerate- ANADA 200-416; Freedom of Information Summary
- » Freedom of Information Summary ANDA 200-318 Bimectin Pour-On (Ivermectin)
- CFR: (2)
- 21 CFR 510.600
- 21 CFR 522.2690